Inhibition of GSK3 dependent tau phosphorylation by metals

Current Alzheimer Research

Volumn 3, Issue 2, 2006, Pages 123-127

  Gómez Ramos, Alberto ^a   Domínguez, Jorge ^b   Zafra, Delia ^b   Corominola, Helena ^c   Gomis, Ramon ^c   Guinovart, Joan J ^b   Avila, Jesús ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BERYLLIUM; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INDIRUBIN; LITHIUM; MAGNESIUM; MALEIMIDE; MANGANESE; TAU PROTEIN; TUNGSTATE SODIUM; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYMOLOGY; INHIBITION KINETICS; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEFECT; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW;

ANIMALS; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; METALS; PHOSPHORYLATION; TAU PROTEINS;

EID: 33645802412     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720506776383059     Document Type: Review

References (62)

1. Glenner GG, Wong CW. Alzheimer's disease initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120(3):885-90 (1984).
2. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83(13):4913-7 (1986).
3. Ihara Y, Nukina N, Miura R, Ogawara M. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J Biochem (Tokyo) 99(6):1807-10 (1986).
4. Himmler A, Drechsel D, Kirschner MW, Martin DW Jr. Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains. Mol Cell Biol 9(4):1381-8(1989).
5. Andreadis A, Brown WM, Kosik KS. Structure and novel exons of the human tau gene. Biochemistry 31(43):10626-33 (1992).
6. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42(3 Pt 1):631-9 (1992).
7. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121-59 (2001).
8. Munoz-Montano JR, Moreno FJ, Avila J, Diaz-Nido J. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett 411(2-3):183-8 (1997).
9. Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 280(3):720-5 (2001).
10. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6(12):1664-8 (1996).
11. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29(2):95-102 (2004).
12. Goto S, Yamamoto H, Fukunaga K, Iwasa T, Matsukado Y, Miyamoto E. Dephosphorylation of microtubule-associated protein 2, tau factor, and tubulin by calcineurin. J Neurochem 45(1):276-83 (1985).
13. Gong CX, Liu F, Grundke-Iqbal I, Iqbal K. Post-translational modifications of tau protein in Alzheimer's disease. J Neural Transm 112(6):813-38 (2005).
14. Yang LS, Ksiezak-Reding H. Calpain-induced proteolysis of normal human tau and tau associated with paired helical filaments. Eur J Biochem 233(1):9-17 (1995).
15. Ma Q, Li Y, Du J, Liu H, Kanazawa K, Nemoto T, et al. Copper binding properties of a tau peptide associated with Alzheimer's disease studied by CD, NMR, and MALDI-TOF MS. Peptides 2005.
16. Perez M, Valpuesta JM, de Garcini EM, Quintana C, Arrasate M, Lopez Carrascosa JL, et al. Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy. Am J Pathol 152(6):1531-9 (1998).
17. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3(4):519-26 (1989).
18. Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Yoshida H, Titani K, Ihara Y. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem 270(2):823-9 (1995).
19. Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev 84(2):361-84 (2004).
20. Planel E, Sun X, Takashima A. Role of GSK-3 in Alzheimer's disease pathology. Drug Development Res 56:491-510 (2002).
21. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9(8):2431-8 (1990).
22. Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 3(6):479-87 (2004).
23. Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med 8(3):126-32 (2002).
24. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36(2):131-7 (2004).
25. Grimes CA, Jope RS, The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65(4):391-426 (2001).
26. Frame S, Cohen P, Biondi RM. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 7(6):1321-7 (2001).
27. Cho JH, Johnson GV. Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J Biol Chem 278(1):187-93 (2003).
28. Su Y, Ryder J, Li B, Wu X, Fox N, Solenberg P, et al. Lithium. a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 43(22):6899-908 (2004).
29. Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 22(10):RC221 (2002).
30. Selkoe DJ, Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81(2):741-66 (2001).
31. Inestrosa N, De Ferrari GV, Garrido JL, Alvarez A, Olivares GH, Barria MI, et al. Wnt signaling involvement in beta-amyloid-dependent neurodegeneration. Neurochem Int 41(5):341-4 (2002).
32. Lovestone S, Reynolds CH, The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78(2):309-24 (1997).
33. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J. Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett 453(3):260-4 (1999).
34. Busciglio J, Lorenzo A, Yeh J. Yankner BA, beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14(4):879-88 (1995).
35. Baki L, Shioi J, Wen P, Shao Z, Schwarzman A. Gama-Sosa M. Neve R. Robakis NK. PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J 23(13):2586-96 (2004).
36. Bhat RV, Budd Haeberlein SL, Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 89(6):1313-7 (2004).
37. Martinez A, Castro A, Dorronsoro I, Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 22(4):373-84 (2002).
38. Ring DB, Johnson KW, Henriksen EJ, Nuss JM, Goff D, Kinnick TR, et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 52(3):588-95 (2003).
39. Perez M, Hernandez F, Lim F, Diaz-Nido J, Avila J. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 5(4):301-8 (2003).
40. Gomez-Ramos A, Dominguez J, Zafra D, Corominola H, Gomis R, Guinovart JJ, et al. Sodium tungstate decreases the phosphorylation of tau through GSK3 inactivation. J Neurosci Res 83(2):264-73 (2006).
41. Dominguez JE, Munoz MC, Zafra D, Sanchez-Perez I, Baque S, Caron M, et al. The antidiabetic agent sodium tungstate activates glycogen synthesis through an insulin receptor-independent pathway. J Biol Chem 278(44):42785-94 (2003).
42. Cho JH, Johnson GV. Glycogen synthase kinase 3 beta induces caspase-cleaved tau aggregation in situ. J Biol Chem 279(52): 54716-23 (2004).
43. Lim F, Hernandez F, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol Cell Neurosci 18(6):702-14 (2001).
44. rd, et al. Reduced binding of protein phosphatase 2A to tau protein with frontotemporal dementia and parkinsonism linked to chromosome 17 mutations. J Neurochem 75(5):2155-62 (2000).
45. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 102(19):6990-5 (2005).
46. Bhat R, Xue Y, Berg S, Hellberg S, Ormo M. Nilsson Y, et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 278(46):45937-45 (2003).
47. Gould TD, Chen G, Manji HK. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 29(1):32-8 (2004).
48. Ryves WJ, Dajani R, Pearl L, Harwood AJ. Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochem Biophys Res Commun 290(3):967-72 (2002).
49. Hong M, Lee VM. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 272(31):19547-53 (1997).
50. Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L, Henry RR, Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 49(2):263-71 (2000).
51. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimers Dis 7(1):63-80 (2005).
52. de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis 7(1):45-61 (2005).
53. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, et al. Reduced hippocampal insulin-degrading enzyme in lateonset Alzheimer's disease is associated with the apolipoprotein Eepsilon4 allele. Am J Pathol 162(1):313-9 (2003).
54. Artola A, Kamal A, Ramakers GM, Biessels GJ, Gispen WH. Diabetes mellitus concomitantly facilitates the induction of long-term depression and inhibits that of long-term potentiation in hippocampus. Eur J Neurosci 22(1):169-78 (2005).
55. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53(9):1937-42 (1999).
56. Biessels GJ, Kappelle LJ. Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans 33(Pt 5):1041-4 (2005).
57. Freude S, Plum L, Schnitker J, Leeser U, Udelhoven M, Krone W, et al. Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes 54(12):3343-8 (2005).
58. Zhu X, Perry G, Smith MA. Insulin signaling, diabetes mellitus and risk of Alzheimer disease. J Alzheimers Dis 7(1):81-4 (2005).
59. Hoyer S. Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm 105(4-5):415-22 (1998).
60. Cheng B, Mattson MP. Glucose deprivation elicits neurofibrillary tangle-like antigenic changes in hippocampal neurons: prevention by NGF and bFGF. Exp Neurol 117(2):114-23 (1992).
61. Planel E, Miyasaka T, Launey T, Chui DH, Tanemura K, Sato S, et al. Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease. J Neurosci 24(10):2401-11 (2004).
62. Jope RS. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 24(9):441-3 (2003).